CoChat

Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Open access
Chu, Alexandro W.L., Wong, Melanie M., Rayner, Daniel G., Guyatt, Gordon H., Díaz Martinez, Juan Pablo, Ceccacci, Renata, Zhao, Irene X., McMullen, Eric, Srivastava, Archita, Wang, Jason, Wen, Aaron, Wang, Fang Chi, Brignardello-Petersen, Romina, Izcovich, Ariel, Oykhman, Paul, Wheeler, Kathryn E., Wang, Julie, Spergel, Jonathan M., Singh, Jasvinder A., Silverberg, Jonathan I., Ong, Peck Y., O’Brien, Monica, Martin, Stephen A., Lio, Peter A., Lind, Mary Laura, LeBovidge, Jennifer, Kim, Elaine, Huynh, Joey, Greenhawt, Matthew, Gardner, Donna D., Frazier, Winfred T., Ellison, Kathy, Chen, Lina, Capozza, Korey, De Benedetto, Anna, Boguniewicz, Mark, Smith Begolka, Wendy, Asiniwasis, Rachel N., Schneider, Lynda C., Chu, Derek K. · 2023 · Journal of Allergy and Clinical Immunology
Cited by 168

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Atopic dermatitis (AD) is an inflammatory skin condition with multiple systemic treatments and uncertainty regarding their comparative impact on AD outcomes. OBJECTIVE: We sought to systematically synthesize the benefits and harms of AD systemic treatments. METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, Web of Science, and GREAT databases from inception to November 29, 2022, for randomized trials addressing systemic treatments and phototherapy for AD. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random-effects network meta-analyses addressed AD severity, itch, sleep, AD-related quality of life, flares, and harms. The Grading of Recommendations Assessment, Development and Evaluation approach informed certainty of evidence ratings. This review is registered in the Open Science Framework (https://osf.io/e5sna). RESULTS: The 149 included trials (28,686 patients with moderate-to-severe AD) evaluated 75 interventions. With high-certainty evidence, high-dose upadacitinib was among the most effective for 5 of 6 patient-important outcomes; high-dose abrocitinib and low-dose upadacitinib were among the most effective for 2 outcomes. These Janus kinase inhibitors were among the most harmful in increasing adverse events. With high-certainty evidence, dupilumab, lebrikizumab, and tralokinumab were of intermediate effectiveness and among the safest, modestly increasing conjunctivitis. Low-dose baricitinib was among the least effective. Efficacy and safety of azathioprine, oral corticosteroids, cyclosporine, methotrexate, mycophenolate, phototherapy, and many novel agents are less certain. CONCLUSIONS: Among individuals with moderate-to-severe AD, high-certainty evidence demonstrates that high-dose upadacitinib is among the most effective in addressing multiple patient-important outcomes, but also is among the most harmful. High-dose abrocitinib and low-dose upadacitinib are effective, but also among the most harmful. Dupilumab, lebrikizumab, and tralokinumab are of intermediate effectiveness and have favorable safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2023.08.029

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 38 references

Cited by

See all 168

Metadata

Authors
Chu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Díaz Martinez, J. P., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., Wang, J., Wen, A., Wang, F. C., Brignardello-Petersen, R., Izcovich, A., Oykhman, P., Wheeler, K. E., Wang, J., Spergel, J. M., Singh, J. A., Silverberg, J. I., Ong, P. Y., O’Brien, M., Martin, S. A., Lio, P. A., Lind, M. L., LeBovidge, J., Kim, E., Huynh, J., Greenhawt, M., Gardner, D. D., Frazier, W. T., Ellison, K., Chen, L., Capozza, K., De Benedetto, A., Boguniewicz, M., Smith Begolka, W., Asiniwasis, R. N., Schneider, L. C., & Chu, D. K.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2023-12
Volume
152
Issue
6
Pages
1470-1492
ISSN
0091-6749 (ISSN-L)
OpenAlex
W4386530720
Cited by
168
References
38
FWCI
12.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. https://app.cochat.ai/papers/10.1016/j.jaci.2023.08.029
The paper
Chu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Díaz Martinez, J. P., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., Wang, J., Wen, A., Wang, F. C., Brignardello-Petersen, R., Izcovich, A., Oykhman, P., Wheeler, K. E., Wang, J., Spergel, J. M., Singh, J. A., . . . Chu, D. K. (2023). Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.08.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.